Q3 2025 Management View CEO Kabir Nath highlighted "the potential 9- to 12-month acceleration of our launch plans that we ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a patent filing and ...

Compass Pathways, which is developing a psilocybin treatment for severe depression, said it now expects an earlier decision ...

Compass Pathways PLC (CMPS) reveals significant progress in clinical trials and strategic initiatives, despite financial challenges.

Drug developer Compass Pathways said on Tuesday it is pulling forward the expected launch of its experimental psilocybin-based depression therapy by 9 to 12 months, sending its shares nearly 6% higher ...

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. COMPASS Pathways Plc is one of them. COMPASS Pathways Plc (NASDAQ:CMPS), a biotechnology company specializing in ...

Compass Pathways remains rated a Hold as I await 26-week phase 3 COMP006 data for treatment-resistant depression expected in the 2nd half of 2026. COMP360 met primary endpoint at six weeks for TRD, ...